ARTICLE | Clinical News

Zevalin ibritumomab tiuxetan: Phase III data

January 30, 2012 8:00 AM UTC

Researchers at the Chaim Sheba Medical Center and colleagues reported data from an open-label, Israeli Phase III trial in 43 patients with CD20+ relapsed or refractory aggressive lymphoma showing that conditioning with 0.4 mCi/kg Zevalin followed by high-dose chemotherapy and ASCT non-significantly improved the 2-year PFS rate, the primary endpoint, vs. high-dose chemotherapy alone given 1-6 days prior to ASCT (59% vs. 37%, p=0.2). Zevalin followed by high-dose chemotherapy and ASCT did significantly improve the 2-year OS rate vs. high-dose chemotherapy alone (91% VS. 62%, p=0.05). Spectrum said the trial was not powered to detect statistical significance on the endpoints. Zevalin was administered 14 days prior to ASCT. Data were published in Cancer. ...